ARCS Closes Pre-Series A Round with Total Funding of Approximately 800 Million Yen
Accelerating Product Development and Business Development in Japan and Abroad
ARCS, which aims to automate assisted reproductive technology, has raised an additional 270 million yen following its 1st close of the Pre-Series A round (approximately 530 million yen) conducted on January 17, 2025, bringing the total for the Pre-Series A round to approximately 800 million yen.
This round includes new investors HIRAC FUND 2, Japan Science and Technology Agency (JST), Asuka Innovation, Mitsubishi UFJ Capital, and Future Creation. Including grants and loans, the company's total funding now amounts to approximately 1.23 billion yen.
Past Initiatives and Use of Funds
Thus far, ARCS has focused primarily on research and development to address challenges in assisted reproductive technology, utilizing grants such as those from the "Deep Tech Startup Support Fund/Deep Tech Startup Support Project (DTSU)/STS Phase" operated by the New Energy and Industrial Technology Development Organization (NEDO) and the "Small and Medium Enterprise Innovation Creation Promotion Project (SBIR)" by the Ministry of Health, Labour and Welfare.
The funds raised will be used not only to continue research and development and clinical research but also for social implementation in Japan and overseas, as well as for recruiting talent as the organization expands.
What is Assisted Reproductive Technology?
Assisted reproductive technology refers to advanced infertility treatments that involve high levels of human intervention, such as in vitro fertilization and intracytoplasmic sperm injection. These treatments have increased dramatically in recent years in developed countries where the maternal age at childbirth is rising. In 2022, one in ten children in Japan was born through assisted reproductive technology. The number of births worldwide through assisted reproductive technology is expected to continue increasing. Assisted reproductive technology offers hope to couples who have difficulty conceiving naturally.
On the other hand, for medical institutions providing assisted reproductive technology, it is not easy to maintain and ensure the quality of medical care and improve the success rate of treatment. The company will continue to advance research and development toward realizing a society where the quality of infertility treatment is enhanced and more people can receive treatment with peace of mind.